ArticleNature communications2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
Abstract readPublished Erratum
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum for
Authors and funding
33 authors.
Daniel B Reeves *Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. dreeves@fredhutch.org.ORCID http://orcid.org/0000-0001-5684-9538
Bryan T Mayer *Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-2258-5276
Allan C deCampVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1404-4322
Yunda HuangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1546-6172
Bo ZhangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-4381-1124
Lindsay N CarppVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-0333-5925
Craig A MagaretVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-5056-2664
Michal JuraskaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-0920-2915
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2662-9427
David C MontefioriDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0003-0856-6319
Katharine J BarPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-9773-0071
E Fabian Cardozo-OjedaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-8690-9896
Joshua T SchifferVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2598-1621
Raabya RossenkhanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Paul EdlefsenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-8393-8103
Lynn MorrisNational Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.ORCID http://orcid.org/0000-0003-3961-7828
Nonhlanhla N MkhizeNational Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
Carolyn WilliamsonDivision of Medical Virology, Faculty of Health Sciences, University of Cape Town and National Health Laboratory Service, Cape Town, South Africa.ORCID http://orcid.org/0000-0003-0125-1226
James I MullinsDepartment of Global Health, University of Washington, Seattle, WA, USA.
Kelly E SeatonCenter for Human Systems Immunology, Duke University, Durham, NC, USA.ORCID http://orcid.org/0000-0002-2009-3270
Georgia D TomarasCenter for Human Systems Immunology, Duke University, Durham, NC, USA.ORCID http://orcid.org/0000-0001-8076-1931
Philip AndrewFamily Health International, Durham, NC, USA.
Nyaradzo MgodiClinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Julie E LedgerwoodVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Myron S CohenInstitute for Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2179-2436
Logashvari NaidooSouth African Medical Research Council, HPRU, Durban, South Africa.
Catherine OrrellDesmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa.
Paul A GoepfertDivision of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0001-8441-5737
Martin CasapiaFacultad de Medicina Humana, Universidad Nacional de la Amazonia Peru, Iquitos, Peru.ORCID http://orcid.org/0000-0002-5972-0948
Magdalena E SobieszczykDivision of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian/Columbia University Irving Medical Center, New York, NY, USA.
Shelly T KarunaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-5946-9733
Srilatha EdupugantiDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MSDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MSDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9MUZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9MUZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3MStatistical Methods in HIV Vaccine Efficacy TrialsR37AI054165 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert · 2010 to 2026
$6.7MNIAID NIH HHS R37 AI054165NIAID NIH HHS U01 AI069436NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069436
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.